A Phase I First-in-Human Dose Escalation Trial to Evaluate the Safety and Efficacy of ARI-HER2 (HER2BBz CAR-T Cells) in Patients with HER2Positive Advanced Breast Cancer

Status

Withdrawn

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521052-35-00

Acronym

ARI-HER2

Enrollment

Registered

2025-10-15

Start date

Unknown

Completion date

Unknown

Last updated

2025-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with HER2Positive Advanced Breast Cancer

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026